Our $9.00 price target on WELL Health could soon go higher, Stifel says

Stifel analyst Justin Keywood said WELL Health Technologies’ (WELL Health Technologies Stock Quote, Chart, News, Analysts, Financials TSX:WELL) latest acquisition underscores disciplined execution against its 2026 objectives, reinforcing the case for further scale-driven value creation across its Canadian clinic platform.

WELL currently operates more than 230 clinics across Canada, representing about 1.6% market share, making it the country’s largest clinic operator.

In a Feb. 4 note, Keywood reiterated a “Buy” rating and C $9.00 target on WELL Health Technologies following the company’s announcement that it will acquire E-Consult Canada, an e-consultation healthcare services provider with an affiliated network of eight primary care clinics in Alberta.

“We believe as the 2026 playbook is executed, the concurrent 2x credit facility expansion provides growth capital to continue scaling the Canadian network, and should catalyze a re-rating in shares..”

The transaction carries cash consideration of C$33-million, with E-Consult expected to generate approximately C$45-million in annualized revenue at Adjusted EBITDA margins above 20%. On a pre-synergy basis, the deal implies revenue and Adjusted EBITDA multiples of 0.7x and 3.7x, respectively, levels Keywood described as meaningfully more attractive than prior Canadian primary care clinic transactions, which have typically been completed closer to 6.0x EBITDA.

The acquisition further expands WELL’s Alberta footprint, a province the analyst continues to view as structurally attractive given policy shifts such as Bill 11, which support expanded private-pay healthcare delivery and improved clinic economics. Keywood said this dynamic supports margin expansion over time and aligns with WELL’s stated objective of scaling its Canadian clinic presence.

Stifel data show WELL has been steadily accelerating clinic M&A since late 2024. Across 2024–2026 year-to-date, WELL has completed 52 clinic acquisitions for a total consideration of roughly C$102-million, equating to an average capital intensity of about C$2.0-million per clinic. The E-Consult transaction stands out within that broader history, both for its larger scale and its materially higher margin profile. The accompanying acquisition trend data also highlight a sharp increase in deployed capital and clinic additions entering 2026, consistent with management’s stated pivot toward higher-quality, accretive assets.

In parallel with the acquisition, WELL announced a significant expansion of its WHCC/MyHealth credit facility to C$400-million from C$150-million, with maturity extended to January 2030 from July 2027. On a pro forma basis, Keywood estimates net debt-to-EBITDA remains below 3.0x, providing what he described as ample capacity to continue executing on Canadian clinic consolidation. He noted the expanded facility supports WELL’s long-term ambition to grow its Canadian market share from roughly 1.6% today toward 10% over time.

Keywood added that the E-Consult deal reflects management’s stated intent to prioritize Canadian assets as U.S. divestiture processes continue. WELL updated its M&A pipeline to approximately 120 potential assets, representing about C$370-million in combined revenue, compared with its existing Canadian clinic network of roughly 240 clinics generating about C$440-million in run-rate sales. The analyst said the composition of the pipeline increasingly skews toward higher-margin primary care, longevity, executive health, and diagnostic assets.

Stifel estimates that Canadian clinic targets under LOI have increased nearly fourfold quarter over quarter and more than twelvefold since Q4 2024, with combined target revenue rising from C$48-million in Q2 2025 to C$245-million in the most recent update. Keywood said this creates a substantial opportunity to redeploy proceeds from potential U.S. asset sales into higher-return domestic acquisitions.

On valuation, Keywood said WELL continues to screen attractively at approximately 8.3x 2026E EBITDA, versus 12.1x for traditional healthcare service providers and 13.4x for tech-enabled healthcare peers. He said ongoing simplification initiatives, including prospective U.S. divestitures and execution of the 2026 playbook, should support a re-rating as higher-margin growth becomes more visible.

“We believe as the 2026 playbook is executed, the concurrent 2x credit facility expansion provides growth capital to continue scaling the Canadian network, and should catalyze a re-rating in shares,” the analyst added.

Disclosure: Nick Waddell owns shares of WELL Health and the company is an annual sponsor.

-30-